Teva completes acquisition of Labrys
21 July 2014 | By Teva
...opens door to a strong and novel migraine prevention and treatment franchise within its CNS portfolio.
List view / Grid view
News
Thermo Fisher Scientific transforms chromatography by reimagining UHPLC
Thermo Fisher Scientific, the world leader in serving science, today unveiled a new high performance liquid chromatography system designed from the ground up to provide new levels of performance, productivity and usability when used as a standalone system or with the latest mass spectrometers
AstraZeneca reveals designs for new Global R&D Centre and Corporate Headquarters in Cambridge, UK
18 July 2014 | By AstraZeneca
AstraZeneca revealed the proposed designs for its new Global R&D Centre and Corporate Headquarters in Cambridge in the UK...
Amgen announces positive Phase 3 results for AMG 416 for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease receiving hemodialysis
18 July 2014 | By Amgen
Amgen announced that a Phase 3 study evaluating AMG 416 (formerly known as velcalcetide) for the treatment of secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease...
Trametinib (Mekinist™) and dabrafenib (Tafinlar™) combination demonstrated overall survival benefit compared to vemurafenib
18 July 2014 | By GlaxoSmithKline
...phase III BRAF V600-mutant metastatic melanoma study stopped early.
Bristol-Myers Squibb and Pfizer announce enrollment of first patient in Phase IV EMANATE trial to assess effectiveness and safety of Eliquis® (apixaban) in patients with NVAF undergoing cardioversion
18 July 2014 | By Bristol-Myers Squibb Company
Bristol-Myers Squibb Company and Pfizer Inc. announced that the first patient has been enrolled into a Phase IV clinical trial called EMANATE assessing the effectiveness and safety of Eliquis in patients with nonvalvular atrial fibrillation undergoing cardioversion...
Roche announces phase II clinical results of crenezumab in Alzheimer’s disease
17 July 2014 | By Roche
Roche presented data from two phase II studies investigating whether crenezumab can delay cognitive and functional decline in people with mild-to-moderate Alzheimer’s disease...
Leading U.S. proxy advisory firm supports Teva nominees and other shareholders’ meeting proposals
17 July 2014 | By Teva
Teva Pharmaceutical Industries Ltd. reported that ISS Proxy Advisory Services, the leading U.S. independent proxy advisory firm, recommended that shareholders vote in favor of all Teva nominees for director...
Pfizer announces positive top-line results from Phase 3 study of NONACOG ALFA (BeneFIX®) once-weekly prophylaxis for hemophilia B
17 July 2014 | By Pfizer
Pfizer Inc. announced the positive results of a Phase 3 study comparing a prophylaxis regimen of BeneFIX® Coagulation Factor IX (Recombinant) 100 IU/kg once-weekly to on-demand treatment in people with moderately severe to severe hemophilia B...
Boehringer Ingelheim’s investigational therapy nintedanib* receives the first FDA breakthrough therapy designation in IPF
17 July 2014 | By Boehringer Ingelheim
Boehringer Ingelheim announced that for the first time the U.S. Food & Drug Administration has granted Breakthrough Therapy designation for a treatment in idiopathic pulmonary fibrosis...
GSK and Theravance announce initiation of phase III programme with fixed dose triple combination treatment FF/UMEC/VI in patients with COPD
16 July 2014 | By GlaxoSmithKline
GlaxoSmithKline plc and Theravance, Inc. announced the start of a global phase III study, known as IMPACT, to evaluate the efficacy and safety of the ‘closed’ triple combination of FF/UMEC/VI in patients with chronic obstructive pulmonary disease...
Biogen Idec and Yahoo Health spotlight visionaries whose work benefits people with multiple sclerosis (MS)
16 July 2014 | By Biogen Idec
Biogen Idec announced a new program with Yahoo Health to raise awareness of innovative efforts to help people with multiple sclerosis across the country...
Tecan launches new options for Cavro® Omni Robot at AACC’s Clinical Lab Expo
15 July 2014 | By kdm communications
Tecan has extended the flexibility of its popular Cavro® Omni Robot with the introduction of embedded control functions and the option to select single axis configurations...
Actavis confirms generic Diclegis® Patent challenge
15 July 2014 | By Actavis
Actavis plc confirmed that it has filed an Abbreviated New Drug Application with the FDA seeking approval to market Doxylamine Succinate and Pyridoxine Hydrochloride Delayed-release tablets...
Novartis announces collaboration with Banner Alzheimer’s Institute on a pioneering prevention study for Alzheimer’s Disease
15 July 2014 | By Novartis
Novartis announced a collaboration with Banner Alzheimer's Institute on a pioneering clinical study in Alzheimer's disease (AD) prevention...
